| |FEBRUARY 20268LUPIN LAUNCHES NEW EPILEPSY DRUG FOR PARTIAL-ONSET SEIZURESSUN PHARMACEUTICAL TO INVEST RS 500 CRORE IN ASSAM PLANTSun Pharmaceutical will establish a new manufacturing facility in the Indian state of Assam with an approximate investment of Rs 500 crore. The project is expected to create direct employment opportunities for over 500 people once the plant begins operations.Senior officials from Sun Pharmaceutical met the chief secretary on Wednesday to discuss key aspects of rolling out the project. "Held a meeting with representatives of Sun Pharmaceutical Industries Limited... to review the company's proposal for setting up pharmaceutical manufacturing facilities in Assam," Chief Secretary Ravi Kota said in an X post on Wednesday.The company was represented by senior vice president Rahul Awasthi and associate vice president Ranjit Mohapatra during the meeting. According to Kota, "The proposal involves establishing drug formulation manufacturing units in the state to cater to the Indian market, with a planned investment of over Rs 500 crore to be implemented in two phases."The project will be executed in stages, with hiring also planned in phases. "The project is expected to generate direct employment for more than 500 people in a phased manner after commencement of operations," the chief secretary said.Several other factors were also discussed between government and private sector representatives including land needs, water availability, power availability, transport infrastructure and skilled labour/supply issues. The company also discussed their plans related to sustainable manufacturing which included water conservancy methods, renewable energy sources and responsible waste management procedures, all consistent with appropriate environmental regulations."The meeting was part of the Assam government's ongoing engagement with prospective investors to promote employment generation, inclusive development, and long-term economic growth in the state," Kota added. POTOP STORIESLupin Pharmaceuticals has officially launched its new epilepsy drug in the U.S. market. Lacosamide Tablets, the product is currently being sold as a prescription medication used in adults with partial-onset seizures.This is an important milestone in the history of Lupin since the firm is diversifying its products in the epilepsy treatment market. It is a generic to the UCB Vimpat drug which is already approved by the FDA.Epilepsy is a disease that afflicts millions of individuals all over the world and considering that partial-onset seizures are a widely spread form of this condition, the need to find an efficient means of treatment remains high.Lacosamide is created to help in controlling these seizures and it provides the patients with an option that could make their lives better. The new product comes in various strengths and thus it can be used by a great number of patients.Lupin's CEO, Vinita Gupta, expressed excitement about the launch, noting that this drug strengthens the company's commitment to providing affordable treatments for complex conditions. She added, "We are proud to bring this important treatment to patients in the U.S., further expanding our specialty portfolio."The introduction is timed with the fact that the epilepsy treatment market faces heightened awareness of where the trend is moving in offering a better and more accessible care. The move by Lupin into this market makes it a firm in the global pharmaceutical market, where it deals with high quality generic substitutes. PO
< Page 7 | Page 9 >